Core Viewpoint - China Resources Pharmaceutical (03320) announced plans to establish a fund with an expected scale of 500 million yuan, focusing on investments in high-growth companies in synthetic biology, innovative drugs, and biotechnology sectors [2][2]. Company Summary - The fund will involve China Resources Pharmaceutical (Shantou), China Resources Double Crane, Double Crane (Beijing), and China Resources Pharmaceutical Investment, along with Hanwei Huayou Shantou and other interested partners [2][2]. - China Resources Pharmaceutical plans to commit a total investment of no more than 123 million yuan, accounting for approximately 24.6% of the total committed capital of the fund [2][2]. - The fund is expected to be managed by Shenzhen China Resources Capital and will not be accounted as a subsidiary of China Resources Pharmaceutical upon establishment [2][2]. Related Parties - Hanwei Huayou Shantou is a wholly-owned subsidiary of China Resources Investment (Tianjin), which is ultimately held by China Resources Group, the controlling shareholder of China Resources Pharmaceutical, thus constituting a related party transaction [2][2]. Business Overview - Established in 2007, China Resources Pharmaceutical operates in the manufacturing and commercial distribution of pharmaceuticals, health products, and medical devices [2][2]. - The company owns several subsidiaries, including China Resources Pharmaceutical Commercial Group Co., Ltd., China Resources Sanjiu Medical & Pharmaceutical Co., Ltd., China Resources Double Crane Pharmaceutical Co., Ltd., China Resources Jiangzhong Pharmaceutical Group Co., Ltd., and Dong'e Ejiao Co., Ltd. [2][2]. Financial Performance - In 2024, China Resources Pharmaceutical achieved operating revenue of 257.673 billion yuan, representing a year-on-year growth of 5.3% [2][2]. - The net profit attributable to the parent company was 3.351 billion yuan, showing a year-on-year decline of 13.06% [2][2].

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示： ● 交易简要内容：华润双鹤药业股份有限公司(以下简称"华润双鹤"或"公司")拟投资设立华润双鹤生物 医药产业基金(呼和浩特)投资合伙企业(有限合伙)(暂定名，以工商核准名为准，以下简称"华润双鹤产 业基金"或"该基金")，基金目标募集规模为5亿元人民币，公司及全资子公司双鹤(北京)生物技术有限公 司(以下简称"双鹤生物")拟以自有资金出资不超过8,700万元人民币，占基金总出资额的比例不超过 17.40%。 ● 本次交易构成关联交易，不构成重大资产重组。 ● 本次交易金额超过3,000万元，未超过公司2024年度经审计净资产的5%，已经董事会审议批准，无需 提交股东会审议。 ● 过去12个月内，除日常关联交易及本次交易外，公司拟以自有资金4,000万元人民币与华润医药投资 有限公司等11家合伙人共同投资设立华润医药(成都)创新投资基金合伙企业(有限合伙)(以下简称"华润 医药产业投资基金二期")，基金目标募集规模为10亿元人民币，公司出资比例为4.00%。除前述交 ...

Group 1 - China Resources Pharmaceutical (03320) announced a collaboration to establish a fund with an expected scale of RMB 500 million [1] - The fund is anticipated to focus on high-growth investments in synthetic biology, innovative drugs, and biotechnology sectors [1] - The company plans to commit a total investment of up to RMB 123 million, representing approximately 24.6% of the total committed capital for the fund [1] Group 2 - The fund is expected not to be accounted as a subsidiary of the company after its establishment [1] - Shenzhen China Resources Capital is expected to be appointed as the fund manager [1]

Core Viewpoint - China Resources Pharmaceutical (03320) is collaborating with partners to establish a fund with an expected scale of RMB 500 million, focusing on high-growth investments in synthetic biology, innovative drugs, and biotechnology sectors [1] Company Summary - The company plans to commit a total investment of up to RMB 123 million, which represents approximately 24.6% of the total committed capital for the fund [1] - The fund is expected not to be accounted as a subsidiary of the company after its establishment [1] - Shenzhen China Resources Capital is anticipated to be appointed as the fund manager [1]

Group 1 - China Resources Pharmaceutical (03320) announced a collaboration with its subsidiaries and Hanwei Huayou Shantou to establish a fund with an expected scale of RMB 500 million [1] - The fund is anticipated to focus on high-growth investments in synthetic biology, innovative drugs, and biotechnology sectors [1] - The company plans to commit a total investment of up to RMB 123 million, representing approximately 24.6% of the total fund commitment [1] - The fund is expected not to be accounted as a subsidiary of the company upon establishment [1] - Shenzhen China Resources Capital is expected to be appointed as the fund manager [1]

Group 1 - The core announcement involves China Resources Pharmaceutical (03320.HK) planning to establish a fund with an expected scale of RMB 500 million, focusing on investments in high-growth companies in synthetic biology, innovative drugs, and biotechnology [1] - The company intends to commit a total investment of up to RMB 123 million, which represents approximately 24.6% of the total committed capital for the fund [1] - Shenzhen China Resources Capital is expected to be appointed as the fund manager after its establishment [1]

【环球时报报道 记者 李迅典】"美国加征关税重塑世界贸易格局，韩越领导人承诺深化双边关系。"路 透社11日报道称，应韩国总统李在明邀请，越共中央总书记苏林于8月10日至13日对韩国进行国事访 问。韩国《中央日报》称，这是越共中央总书记11年来首次访韩，苏林也成为李在明上任后接待的首位 外国领导人。 韩联社称，李在明还邀请苏林出席将于10月在庆州举行的亚太经合组织（APEC）第三十二次领导人非 正式会议，苏林对此予以积极回应。 据报道，李在明与苏林11日在首尔龙山总统府举行会谈，宣布计划将双边贸易额从2024年的约868亿美 元提升至2030年的1500亿美元，双方签署多项关键领域合作协议。韩总统办公室称，两国还签署了10项 谅解备忘录，承诺在核能、可再生能源、货币金融政策、科技等领域开展合作。李在明称，两国将加速 推进核电、高速铁路及智慧城市等大型基础设施项目合作，并在人工智能、生物技术、芯片研发等新兴 领域加强协作。他表示，希望 "依托韩国企业卓越的技术实力和丰富经验，涌现出成功的合作案例"。 苏林则呼吁韩方继续为越南培养高端技术人才，并支持韩国企业扩大在越投资规模。 ...

（文章来源：央视新闻） 据中国科学院遗传与发育生物学研究所消息，该研究所许操研究员带领的智能育种攻关团队将BT（生 物技术）与AI（人工智能）深度融合，首次提出作物-机器人协同设计理念，通过基因编辑重新设计作 物花型，快速精准创制"机器人友好"的结构型雄性不育系，运用深度学习和人工智能成功研制出世界首 台可自动巡航杂交授粉的智能育种机器人"吉儿"（GEAIR），打破杂交育种和制种瓶颈，可大幅降低育 种成本、缩短育种周期、提高育种效率。这一成果北京时间8月11日在国际学术期刊《细胞》发表。 ...

Group 1 - The Indian MSCI index has underperformed the Chinese stock market by approximately 10 percentage points this quarter, potentially marking the largest annual performance gap since 2017 [1][4] - Goldman Sachs predicts that the Indian stock market will continue to lag behind other emerging markets, maintaining a "neutral" rating on Indian stocks while reiterating an "overweight" stance on Chinese stocks and raising the 12-month target for the MSCI China index [4][6] - The market dynamics have shifted due to the recent imposition of a 25% additional tariff on Indian goods by Trump, which has led to a significant capital outflow from India, with around $3 billion leaving the market last month, the largest monthly outflow since February [4][6] Group 2 - The trade dispute has reshaped the investment landscape between China and India, with the recent tariff actions being particularly targeted and sudden [5] - The deteriorating US-India relations and new tariffs may undermine India's manufacturing ambitions, causing investor concerns regarding India's high valuations and slowing profit growth [7][8] - In contrast, China offers more attractive investment opportunities in rapidly growing sectors such as artificial intelligence, clean energy, and biotechnology, which may support the "buy China" investment logic in the short term [9]

Core Viewpoint - The imposition of a 25% additional tariff on Indian goods by the Trump administration is reshaping the investment landscape in Asia, leading to a shift from "buying India" to "buying China" among investors [1][2]. Group 1: Market Performance - The MSCI India index has underperformed the Chinese stock market by approximately 10 percentage points this quarter, potentially marking the largest annual performance gap since 2017 [2]. - Foreign investors withdrew about $3 billion from the Indian stock market last month, the highest monthly outflow since February of this year [3][4]. Group 2: Investment Strategy Adjustments - Goldman Sachs maintains a "market weight" view on the Indian stock market while reiterating an "overweight" stance on the Chinese market, raising the 12-month target for the MSCI China index [2][3]. - The market capitalization gap between Chinese and Indian stock markets has widened to $6.3 trillion, the largest since March [2]. Group 3: Trade Relations and Market Sentiment - The sudden and targeted nature of the tariffs has escalated trade tensions, affecting market sentiment and investor confidence in India [3]. - Analysts express concerns over India's high valuations and slowing profit growth, which may lead to further foreign fund sell-offs [3][4]. Group 4: Comparative Valuation - The MSCI India index is currently trading at over 21 times its one-year forward earnings, while the Chinese index is at 11.9 times, making China more attractive for value investors [4]. - The ongoing trade uncertainties may position Indian stocks as secondary in regional allocations, with potential for increased foreign fund selling [4]. Group 5: Long-term Outlook for India - Despite short-term challenges, India's long-term economic trajectory remains appealing to some investors, with Morgan Stanley predicting that India's stock market could reach new highs due to strong population growth and improving fundamentals [5].